Advertisement

The AAPS Journal

, 20:3 | Cite as

Effectiveness of a Cocaine Hydrolase for Cocaine Toxicity Treatment in Male and Female Rats

  • Xirong Zheng
  • Ziyuan Zhou
  • Ting Zhang
  • Zhenyu Jin
  • Xiabin Chen
  • Jing Deng
  • Chang-Guo Zhan
  • Fang Zheng
Research Article Theme: Better Drugs for Better Life: Drug Discovery and Development Colloquium 2017
Part of the following topical collections:
  1. Theme: Better Drugs for Better Life: Drug Discovery and Development Colloquium 2017

Abstract

Development of a truly effective medication for treatment of cocaine abuse has been a grand challenge. There is no FDA-approved therapeutic agent specific for cocaine addiction or overdose. An enzyme therapy using an efficient cocaine-metabolizing enzyme could be a promising treatment strategy for cocaine overdose and addiction. One of our previously designed cocaine hydrolases (CocHs), known as CocH1, was fused with human serum albumin (HSA) to prolong the biological half-life. The fusion protein CocH1-HSA is an investigational new drug (IND) approved by the FDA for clinical trials in cocaine addiction treatment, but not in cocaine overdose/toxicity treatment. In the present study, we aimed to evaluate the pharmacokinetic profile of CocH1-HSA and its effectiveness for cocaine toxicity treatment in male and female rats and demonstrate the clinical potential. The data demonstrate that enzyme CocH1-HSA has very similar pharmacokinetic profile in male and female rats. For both male and female rats, the enzyme can rapidly eliminate cocaine even if the cocaine dose is as high as 180 mg/kg (LD100). Based on the animal data, whenever the enzyme is given to a living subject, the remaining cocaine in the body will be converted rapidly to physiologically inactive metabolites and, thus, reverse the cocaine toxicity and help the subject to recover. So, an enzyme therapy using CocH1-HSA can effectively treat cocaine toxicity and prevent the subject from further damage by cocaine. The data obtained clearly demonstrate the promising clinical potential of CocH1-HSA in cocaine overdose treatment for both genders.

KEY WORDS

Drug abuse Drug overdose Cocaine toxicity Enzyme therapy Drug metabolism 

Notes

Author Contribution

X.Z. and Z.Z. performed in vivo studies and analyzed the data. T.Z. and J.D. contributed to the in vivo studies. X.C. analyzed the blood samples. Z.J. prepared the experimental materials. C.-G.Z. and F.Z. designed the study, analyzed the data, and finalized the manuscript. All authors reviewed the manuscript.

Funding information

This work was supported in part by the National Institutes of Health (NIH grants UH2/UH3 DA041115, R01 DA035552, R01 DA032910, R01 DA013930, and R01 DA025100) and the National Science Foundation (NSF grant CHE-1111761).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Landry DW, Zhao K, Yang GX, Glickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine. Science. 1993;259(5103):1899–901.  https://doi.org/10.1126/science.8456315.CrossRefPubMedGoogle Scholar
  2. 2.
    Milton AL, Everitt BJ. Wiping drug memories. Science. 2012;336(6078):167–8.  https://doi.org/10.1126/science.1221691.CrossRefPubMedGoogle Scholar
  3. 3.
    Ersche KD, Jones PS, Williams GB, Turton AJ, Robbins TW, Bullmore ET. Abnormal brain structure implicated in stimulant drug addiction. Science. 2012;335(6068):601–4.  https://doi.org/10.1126/science.1214463.CrossRefPubMedGoogle Scholar
  4. 4.
    Baingana F, al’Absi M, Becker AE, Pringle B. Global research challenges and opportunities for mental health and substance-use disorders. Nature. 2015;527(7578):S172–S7.  https://doi.org/10.1038/nature16032.CrossRefPubMedGoogle Scholar
  5. 5.
    Holmes D. Addition: 4 big questions. Nature. 2015;522(7557):S63.  https://doi.org/10.1038/522S63a.CrossRefPubMedGoogle Scholar
  6. 6.
    Zheng F, Zhan C-G. Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose? Future Med Chem. 2012;4(2):125–8.  https://doi.org/10.4155/fmc.11.171.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Skolnick P, White D, Acri JB. Editorial: emerging targets for stimulant use disorders: where to invest in an era of constrained resources? CNS Neurol Disord-Drug Targets. 2015;14:691.CrossRefPubMedGoogle Scholar
  8. 8.
    Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, Gross A, et al. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J Clin Pharmacol. 2015;55(5):573–83.  https://doi.org/10.1002/jcph.450.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, et al. Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase and intravenously administered cocaine in recreational cocaine users. J Clin Psychopharmacol. 2015;35(4):396–405.  https://doi.org/10.1097/JCP.0000000000000347.PubMedGoogle Scholar
  10. 10.
    Brimijoin S, Gao Y, Anker JJ, Gliddon LA, LaFleur D, Shah R, et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology. 2008;33(11):2715–25.  https://doi.org/10.1038/sj.npp.1301666.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sun H, Pang Y-P, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol. 2002;62(2):220–4.  https://doi.org/10.1124/mol.62.2.220.CrossRefPubMedGoogle Scholar
  12. 12.
    Pan Y, Gao D, Yang W, Cho H, Yang G, Tai H-H, et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A. 2005;102(46):16656–61.  https://doi.org/10.1073/pnas.0507332102.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zheng F, Yang WC, Ko MC, Liu JJ, Cho H, Gao DQ, et al. Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc. 2008;130(36):12148–55.  https://doi.org/10.1021/ja803646t.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Xue L, Ko M-C, Tong M, Yang W, Hou S, Fang L, et al. Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol. 2011;79(2):290–7.  https://doi.org/10.1124/mol.110.068494.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zheng F, Xue L, Hou S, Liu J, Zhan M, Yang W, et al. A highly efficient cocaine-detoxifying enzyme obtained by computational design. Nat Commun. 2014;5:3457.  https://doi.org/10.1388/ncomms4457. PubMedPubMedCentralGoogle Scholar
  16. 16.
    Hou S, Xue L, Yang W, Fang L, Zheng F, Zhan C-G. Substrate selectivity of high-activity mutants of human butyrylcholinesterase. Org Biomol Chem. 2013;11(43):7477–85.  https://doi.org/10.1039/c3ob41713a.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang W, Xue L, Fang L, Chen X, Zhan C-G. Characterization of a high-activity mutant of human butyrylcholinesterase against (−)-cocaine. Chem Biol Interact. 2010;187(1–3):148–52.  https://doi.org/10.1016/j.cbi.2010.01.004.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Willyard C. Quest for the quitting pill. Nature. 2015;522(7557):S53–5.  https://doi.org/10.1038/522S53a.CrossRefPubMedGoogle Scholar
  19. 19.
    Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, et al. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. Drug Alcohol Depend. 2016;166:13–20.  https://doi.org/10.1016/j.drugalcdep.2016.05.019.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, et al. Long-acting cocaine hydrolase for addiction therapy. Proc Natl Acad Sci U S A. 2016;113(2):422–7.  https://doi.org/10.1073/pnas.1517713113.CrossRefPubMedGoogle Scholar
  21. 21.
    Lockridge O, Schopfer LM, Winger G, Woods JH. Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J Med Chem Biol Radiol Def. 2005;3:nihms5095.  https://doi.org/10.1901/jaba.2005.3-nihms5095.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Chen X, Zheng X, Ding K, Zhou Z, Zhan C-G, Zheng F. A quantitative LC-MS/MS method for simultaneous determination of cocaine and its metabolites in whole blood. J Pharm Biomed Anal. 2017;134:243–51.  https://doi.org/10.1016/j.jpba.2016.11.024.CrossRefPubMedGoogle Scholar
  23. 23.
    Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, et al. Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther. 2007;320(2):926–33.  https://doi.org/10.1124/jpet.106.114223. CrossRefPubMedGoogle Scholar
  24. 24.
    Chen X, Zheng X, Zhan M, Zhou Z-Y, Zhan C-G, Zheng F. Metabolic enzymes of cocaine metabolite benzoylecgonine. ACS Chem Biol. 2016;11(8):2186–94.  https://doi.org/10.1021/acschembio.6b00277.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Barnett G, Hawks R, Resnick R. Cocaine pharmacokinetics in humans. J Ethnopharmacol. 1981;3(2-3):353–66.  https://doi.org/10.1016/0378-8741(81)90063-5.CrossRefPubMedGoogle Scholar
  26. 26.
    Zheng F, Zhan C-G. Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. PLoS Comput Biol. 2012;8(7):e1002610.  https://doi.org/10.1371/journal.pcbi.1002610.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhang T, Zheng X, Zhou Z, Chen X, Jin Z, Deng J, Zhan C-G, Zheng F. Clinical potential of an enzyme-based novel therapy for cocaine overdose. Sci Rep. 2017;7(1):15303.  https://doi.org/10.1038/s41598-017-14105-5.
  28. 28.
    Zhan M, Hou S, Zhan C-G, Zheng F. Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine. Biochem J. 2014;457(1):197–206.  https://doi.org/10.1042/BJ20131100.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Morishima HO, Whittington RA, Iso A, Cooper TB. The comparative toxicity of cocaine and its metabolites in conscious rats. Anesthesiology. 1999;90(6):1684–90.  https://doi.org/10.1097/00000542-199906000-00025.CrossRefPubMedGoogle Scholar
  30. 30.
    Kerver HN, Becker JB. Sex differences in the effects and actions of cocaine. The neuroscience of cocaine: mechanisms and treatment. 2017:edited by Victor R. Preedy, Academic Press p. 663–72.Google Scholar
  31. 31.
    Heard K, Palmer R, Zahniser NR. Mechanisms of acute cocaine toxicity. Open Pharmacol J. 2008;2(9):70–8.  https://doi.org/10.2174/1874143600802010070.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Nasser AF, Fudala PJ, Zheng B, Liu Y, Heidbreder CA. Randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J Addict Dis. 2014;33(4):289–302.  https://doi.org/10.1080/10550887.2014.969603.CrossRefPubMedGoogle Scholar
  33. 33.
    Amin M, Gabelman G, Karpel J, Buttrick P. Acute myocardial infarction and chest pain syndromes after cocaine use. Am J Cardiol. 1990;66(20):1434–7.  https://doi.org/10.1016/0002-9149(90)90529-A.CrossRefPubMedGoogle Scholar
  34. 34.
    Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J. 2007;83(980):389–94.  https://doi.org/10.1136/pgmj.2006.055970.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Cocaine overdose: how much amount of cocaine to overdose? (http://drug.addictionblog.org/cocaine-overdose-how-much-amount-of-cocaine-to-overdose/) (last seen: October 11, 2017).

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  • Xirong Zheng
    • 1
    • 2
  • Ziyuan Zhou
    • 1
    • 2
  • Ting Zhang
    • 1
    • 2
  • Zhenyu Jin
    • 1
    • 2
  • Xiabin Chen
    • 1
    • 2
  • Jing Deng
    • 1
    • 2
  • Chang-Guo Zhan
    • 1
    • 2
  • Fang Zheng
    • 1
    • 2
  1. 1.Molecular Modeling and Biopharmaceutical Center, College of PharmacyUniversity of KentuckyLexingtonUSA
  2. 2.Department of Pharmaceutical Sciences, College of PharmacyUniversity of KentuckyLexingtonUSA

Personalised recommendations